Celsion CEO Michael Tardugno - An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Tardugno speaks with the DAILY about the regulatory timeline and commercialization plans for ThermoDox, including plans to market the heat-activated liposomal-delivery doxorubicin in Asia.
You may also be interested in...
Tardugno speaks with the DAILY about his company’s transition from a device firm to an oncologic development company and about its proprietary technology.
Sorafenib becomes first systemic drug therapy approved for unresectable HCC.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.